Lumbar Spinal Stenosis
Conditions
Interventions
Control group:Control Group:
Patients in the control group will receive a conventional pharmacological treatment regimen, including the following:
Mecobalamin Tablets 0.5mg three times a day (Eisai Ch
elcatonin group:Elcatonin Group:
In addition to the treatment received by the control group, the elcatonin group will be supplemented with elcatonin injection 20 units once a week (Asahi Kasei Pharma
Sponsors
Zhejiang province hospital of Chinese medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In order to be included in this trial, participants have to be: (i) diagnosed with lumbar spinal stenosis combined with osteoporosis in our hospital and currently has no plans for surgery; (ii) between 20 to 75-year-old; (iii) free of immune dysfunction, genetic disorders,or severe cardiovascular diseases; (iv) free from any kind of hormonal or antirheumatic drugs for the two months prior to inclusion;(v) free from allergies to elcatonin; and(vi) able to understand and accept all trial procedures and cooperate with clinical physicians’ practices.
Exclusion criteria
Exclusion criteria: Participants with any one of the following conditions will be excluded from this trial: (i) pregnancy; (ii) severe heart, liver, or renal dysfunction; (iii) tumor; (iv) any hematological, respiratory, or cardiovascular disease; (v)any psychiatric disorder; (vi) any history of spinal surgery and (vii) have received elcatonin therapy for OP in the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oswestry Disability Index;Japanese Orthopaedic Association Scores;Visual Analogue Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| bone mineral density; | — |
Countries
China
Contacts
Public ContactTaotao Xu
Zhejiang province hospital of Chinese medicine
Outcome results
None listed